Comparative Pharmacology
Head-to-head clinical analysis: MYKROX versus THALITONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYKROX versus THALITONE.
MYKROX vs THALITONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MYKROX (metolazone) is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule by blocking the Na+-Cl- cotransporter, leading to increased excretion of sodium, chloride, and water.
Thalidone (chlorthalidone) is a thiazide-like diuretic that inhibits sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance and has a long duration of action (>24 hours).
Adults: 1 mg orally once daily, preferably in the morning.
Oral, 25-100 mg once daily, typically 50 mg daily.
None Documented
None Documented
Terminal elimination half-life: 50–70 hours; achieves steady-state after ~2 weeks of once-daily dosing; prolonged in hepatic impairment but not significantly altered in renal impairment.
Terminal elimination half-life is 40-60 hours, allowing once-daily dosing.
Primarily hepatic metabolism (CYP3A4) to inactive metabolites; renal excretion accounts for <10% as unchanged drug; biliary/fecal excretion of metabolites ~75%.
Primarily renal (approximately 50% unchanged); biliary/fecal elimination minor (<10%).
Category C
Category C
Thiazide-like Diuretic
Thiazide-like Diuretic